It is a link for moving within the page.

  1. HOME
  2. About Otsuka
  3. News Releases
  4. 2020
  5. Otsuka Filed Application in Japan for Approval of Fremanezumab as a Prophylactic Treatment for Migraine

July 29, 2020

Otsuka Pharmaceutical Co., Ltd.

Pharmaceuticals

Otsuka Filed Application in Japan for Approval of Fremanezumab as a Prophylactic Treatment for Migraine色秀视频

Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that an application has been submitted to the Pharmaceuticals and Medical Devices Agency in Japan to seek manufacturing and marketing approval for Teva's fremanezumab. The application is for the indication of preventive treatment of migraine.

Fremanezumab is an anti-CGRP (calcitonin gene-related peptide) monoclonal antibody, administered as a subcutaneous injection for the prevention of chronic and episodic migraine attacks. It is thought that fremanezumab, by targeting the CGRP ligand, inhibits its binding to the CGRP receptor, thereby preventing migraine.

In 2017, Otsuka entered into an exclusive licensing agreement with Teva for development and sales in Japan. Earlier this year, the two companies announced outcomes from two, pivotal phase 2/3 trials in Japan for fremanezumab. Subjects with chronic migraine (15 or more headache days per month and eight or more migraine days per month) were assessed in one trial and subjects with episodic migraine (between six and 14 headache days per month and four or more migraine days per month) were assessed in the other trial.

In both trials, primary endpoints were achieved with clinical and statistical significance versus placebo. Improvements versus placebo were also shown for secondary endpoints in both trials. No clinically significant adverse events were observed in subjects who received fremanezumab.

A significant unmet medical need exists for patients in Japan with migraine. This is evidenced, for example, by a large retrospective analysis in Japan which showed that a significant proportion of patients who began to receive prophylactic treatment for migraine subsequently discontinued treatment.1 Many of the patients later reinitiated the same treatment or switched treatment, whereas others permanently discontinued treatment.

Teva obtained regulatory approvals for fremanezumab in the U.S. in 2018 and in Europe in 2019, and it is currently available to patients in these regions under the brand name Ajovy®.

  1. 1Real world treatment patterns and patient-reported outcomes in episodic and chronic migraine in Japan: analysis of data from the Adelphi migraine disease specific programme. J Headache Pain 20: 68 (2019).

Information in this news release was current as of the original release date.

吉林旺隆如设备有限公司

Most Recent Releases

十分钟在线观看免费 国产浮力草草影院 4444在线观看免费 国产人做人爱视频 巴樂视频 92在线午夜福利1000和2017 英式禁忌1983 md.pub麻豆传媒 2020精品国产福利观看 秘密教学子豪45话免费 把腿把开学长都给你宿舍 四虎影视最新免费观看 无尽视频 开心娱乐511cc版 雨天的故事完整视频 香蕉福利导福航大全 乌克兰美女12一18 靠逼网站 男人和女人一起吃积积积 香蕉app下载安卓免费下载 亚洲AV国产AV 猛虎视频污污aPP 大臿蕉香蕉大视频在线观看 日本孕妇孕交videos hd 午夜 下面的感觉 国产美女秒拍福利视频 91Chinese honemade video 性福宝app 茄子视频污app污下载 男女暖暖视频 少妇野性狂欢大派对 欧美片AV手机在线观看 swag.live ios 两个人免费视频 0dounaicom2.2.3 就是色 仙人掌免费下载 妈妈的朋友1 柠檬视频NMAV.CC 国产Av巨作 麻豆传媒映画 dounai.app4 4438x23全国大免 67idcon免费视频网站 两个人的视频全免费中文字幕 富二代在线观看视频大全 百媚下载 第一会所 性视频无遮挡免费观看 久久天堂 1268章都市情缘百度网盘 波多野结衣A片33分钟 日本不卡免费一二本 奶水喷溅福利视频在线观看 五十路人妻中出在线播放 升级访问 高清无码一本到东京热 铁牛app污污 pr.九尾妖尾图片 榴莲视频app在哪下载 冈本视频污 小草社区在线观看视频播放 抖阳 国产Chinese在线男同 紧急大通知拿笔记本记好 性福宝app 叶子直播在线观看 唐人街探案3在线观看 波多野结护士中文版在线看 hs视频 任你躁这里总有你喜欢的 最新富二代f2app下载 爱滋初体验5在线观看完整版 国产性狂乱视频 4438x23全国大免 盘他直播app下载官网 欧美性婬美妇 yh8.lⅰve 天堂AV亚洲AV日韩AV在线 小收影院 250pp 乡镇女干部艳史电影 樱桃成视频人APP在线观看 女人的精水喷出来视频 Tom在线观看影院 某猫是什么app 人与狗性交 番茄社區 考拉直播黄 人与动在线观看完整版 99热这里只/这里有精品 2019精品国自产拍在线不卡 字幕网app 饭粒网 汤佳丽 蜜柚app污版 怎么下载蘑菇视频 芊芊视频qq392 在线萝福利莉视频网免费 麻豆在线 芭比视频无限观看 麻生希高清无码中文 国产麻豆原创免费观看 两个人的视频全免费中文字幕 18禁又污又色的视频 苍月女战士 橙子直播app官方下载地址